Unknown PHASE3 INTERVENTIONAL 2-arm NCT02280278

Cytokine-induced Killer Cell Immunotherapy for Surgical Resected Stage III Colorectal Cancer Patients After Chemotherapy

The Effectiveness and Safety of Adjuvant Cytokine-induced Killer Cell Immunotherapy for Stage III Colorectal Cancer Patients After Chemotherapy

Sponsor: Sun Yat-sen University

Conditions Stage III Colon Cancer

Interventions Adjuvant chemotherapy Cytokine-induced killer cell immunotherapy Radical surgery

Updated 7 times since 2017 Last updated: Nov 3, 2014 Started: Oct 31, 2014 Primary completion: Oct 31, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02280278, this PHASE3 trial focuses on Stage III Colon Cancer and remains ongoing. Sponsored by Sun Yat-sen University, it has been updated 7 times since 2014, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE3
Nov 2019 — Jan 2021 [monthly]

Unknown Status PHASE3

Status: Recruiting → Unknown Status
Jun 2018 — Nov 2019 [monthly]

Recruiting PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Recruiting PHASE3
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE3

First recorded

Oct 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sun Yat-sen University

Data source: Sun Yat-sen University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guagzhou, China